Anissa Kalinowski

Anissa Kalinowski

Company: Halo Biosciences

Job title: Chief Executive Officer


Pipeline Peak 3: Clinical Validation of a New Therapeutic Target: Inhibiting Hyaluronan to Treat Lung Fibrosis & Pulmonary Hypertension 9:20 am

Summarizing emerging data supporting the inhibition of the extracellular matrix glycosaminoglycan hyaluronan (HA) to address fibrotic pulmonary disease Reviewing the results of phase 1 study investigating an HA synthesis inhibitor Previewing two investigational Phase 2a studies of an HA inhibitor currently underway in pulmonary hypertension and progressive pulmonary fibrosisRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.